13:29:45 EDT Thu 25 Apr 2024
Enter Symbol
or Name
USA
CA



Aegerion Pharmaceuticals Observes Rare Disease Day

2015-02-28 07:15 ET - News Release

CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc.(Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS) and Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.

Chief Executive Officer Marc D. Beer commented, "We are proud to join with others in the community to raise awareness of rare diseases. We are mindful of the challenges these patients, their families and caregivers face daily, and we are motivated by a passion to support awareness, advocacy and the development of treatments for these rare diseases."

In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was established by EURORDIS and was first observed in Europe in 2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S. For more information about Rare Disease Day, visit www.rarediseaseday.us or www.rarediseaseday.org.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.  For more information about the company, please visit www.aegerion.com.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Associate Director, Investor Relations & Public Relations
         857-242-5024

Aegerion Pharmaceuticals, Inc. Logo

© 2024 Canjex Publishing Ltd. All rights reserved.